-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Baokang Shiyun-B (02592.HK) announced that Cloudbreak Therapeutics LLC (Cloudbreak USA), a wholly-owned subsidiary of the Company registered in California, United States of America (US), is scheduled to officially hold a Phase 2 post-clinical trial meeting with the US Food and Drug Administration (US Food and Drug Administration) on December 10, 2025. The conference involves the Group's clinical-stage drug candidate CBT-004.

Zhitongcaijing·12/08/2025 04:33:02
Listen to the news
Zhitong Finance App News, Baokang Shiyun-B (02592.HK) announced that Cloudbreak Therapeutics LLC (Cloudbreak USA), a wholly-owned subsidiary of the Company registered in California, United States of America (US), is scheduled to officially hold a Phase 2 post-clinical trial meeting with the US Food and Drug Administration (US Food and Drug Administration) on December 10, 2025. The conference involves the Group's clinical-stage drug candidate CBT-004.